Bremelanotide Rx

Bremelanotide Rx / Evidence

What does PT-141 actually do in the body

By the Bremelanotide Rx Editorial Team · 23 min read

Last updated 2026-07-24

TL;DR

PT-141 (bremelanotide) activates melanocortin receptors in the brain, mainly MC4R, to increase sexual desire from the inside out. It's FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder. Unlike sildenafil, it doesn't work on blood vessels. In phase 3 trials it modestly outperformed placebo on desire scores; nausea and flushing were the trade-off [1][2].

What is PT-141 and what does it actually do

PT-141 is the research name for bremelanotide, a synthetic peptide that mimics a natural brain hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). It's FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, and it works by activating melanocortin receptors in the central nervous system, not by changing blood flow anywhere [1]. That's the single most important thing to understand about it. It's a brain drug, not a plumbing drug. It doesn't relax smooth muscle or dilate vessels the way sildenafil (Viagra) does. Instead it acts on melanocortin receptor pathways, particularly MC4R, that sit upstream of the whole desire and arousal cascade [2] [3]. The drug got FDA approval in 2019 after two identically designed phase 3 trials (the RECONNECT studies) showed a small but statistically real improvement in desire scores and a drop in the distress that comes with low desire, compared to placebo [4]. It's injected subcutaneously, in the abdomen or thigh, roughly 45 minutes before anticipated sexual activity, and its effect is meant to fade within about 24 hours [5]. If you want the fuller pharmacology picture, including receptor subtypes and dosing history, the pt 141 peptide overview covers that ground in more depth.

How does PT-141 work in the brain (the central mechanism)

PT-141 is a melanocortin receptor agonist. It binds mainly to MC4R, a receptor concentrated in the hypothalamus and other brain regions tied to appetite, energy balance, and sexual motivation [3] [6]. When it activates MC4R, it appears to shift the balance of neural signals that either promote or inhibit sexual desire, tipping things toward the promoting side [7]. This is fundamentally different from how PDE5 inhibitors like sildenafil work. Sildenafil acts locally, in genital tissue, by boosting nitric-oxide-mediated blood flow so that physical arousal (erection, genital engorgement) can happen more easily once a person is already mentally interested. PT-141 doesn't touch that pathway at all. It works upstream, in the brain, on the motivational and desire circuitry itself [2] [8]. A 2022 review in CNS Spectrums lays out this neurobiology directly, describing bremelanotide's action on central melanocortin pathways as distinct from peripheral vascular mechanisms, and tying that to why it's approved for a desire disorder rather than an arousal or erectile disorder [8]. Melanocortin receptors also sit in metabolic pathways tied to body weight and energy regulation, which is part of why researchers are separately studying melanocortin agonists for obesity and why some phase 1 bremelanotide trials measured weight change in obese women as a secondary outcome, not the primary one [9] [6]. Worth being honest about: the exact chain of events between MC4R activation and a person subjectively feeling more desire isn't fully mapped out. Researchers can describe the receptor biology and the population-level trial outcomes with confidence. The precise neural circuit-by-circuit story of how that translates into a felt increase in wanting sex is still being filled in [7] [8].

Is PT-141 the same as female Viagra

No, and this comparison causes more confusion than almost anything else about the drug. Sildenafil (Viagra) is a PDE5 inhibitor that works on vascular tissue to support blood flow. PT-141 is a melanocortin agonist that works on brain receptors to affect desire. They don't share a mechanism, a target organ, or even the same category of sexual complaint they're meant to treat [2] [10]. The nickname "female Viagra" got attached early to bremelanotide in academic writing, including a 2006 review literally titled that question mark included [10]. But even that paper was framing it as a hopeful comparison for lay audiences, not a mechanistic one. Viagra fixes a plumbing problem once desire and mental arousal are already present. PT-141 is approved for a desire problem, HSDD, where physical function may be completely normal but interest itself has dropped and is causing distress [1] [11]. A 2021 piece in Drug and Therapeutics Bulletin pushed back hard on how these drugs (bremelanotide and flibanserin) get compared to erectile dysfunction treatments, calling that comparison a "fallacy of regulatory precedent" and arguing the effect sizes and disease framing don't map cleanly onto the male sexual dysfunction model at all [12]. That's a fair critique to sit with before assuming PT-141 will feel like a female equivalent of a well-known erectile drug. It won't.

What is PT-141 approved to treat

PT-141, as Vyleesi, is FDA-approved specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, and only for that indication [1] [4]. Acquired means desire used to be normal and then dropped. Generalized means it's not limited to one partner or one specific situation. It's not approved for postmenopausal women, for men, or for situational low desire tied to a specific relationship problem, stress period, or another medication's side effect. The two key phase 3 studies, published in Obstetrics and Gynecology in 2019, enrolled premenopausal women specifically and measured desire using the Female Sexual Function Index (FSFI) desire domain, alongside a distress scale (FSDS-DAO) [4]. A 2021 review in the Journal of Midwifery & Women's Health frames HSDD within the larger picture of female sexual dysfunction, noting that assessment and diagnosis require ruling out other causes (relationship issues, mental health conditions, medication side effects) before HSDD becomes the working diagnosis [13]. That diagnostic step matters. PT-141 is not a general libido booster for anyone who feels their interest in sex isn't what they'd like; it's built around a specific, ruled-in diagnosis.

How well does PT-141 actually work, according to the trials

In the two RECONNECT phase 3 trials, women taking bremelanotide saw statistically significant improvement in FSFI desire scores compared to placebo, along with a reduction in the distress associated with low desire, measured by FSDS-DAO [4]. That's the headline finding the FDA approval rested on. But "statistically significant" and "large" aren't the same thing, and this is where honest reporting matters. A 2024 paper in the Journal of Sex Research, titled bluntly "Small Effects, Questionable Outcomes," re-examined the bremelanotide trial data and argued the actual clinical effect size was modest, raising questions about how meaningful the improvement feels to an average patient day to day [14]. A separate 2021 re-analysis in the same journal made a similar point about how the phase 3 data was framed [15]. A 2019 responder analysis from an earlier phase 2b dose-ranging study, published in the Journal of Sexual Medicine, looked at what fraction of women hit a meaningful improvement threshold rather than just averaging scores across the whole group, which is a more useful way to think about "will this actually do something for me" [16]. A 2022 subgroup analysis of the RECONNECT data, published in the Journal of Women's Health, broke results down by patient characteristics to see whether certain groups responded better, though it didn't identify a subgroup with a dramatically larger effect [17]. The honest summary: PT-141 clears the bar for FDA approval and produces a real, measurable, but modest average improvement in desire and desire-related distress. It's not a switch that reliably turns desire on for everyone who tries it.

PT-141 (bremelanotide) key clinical facts From FDA approval basis and phase 3 trial data 2,019 FDA approval year (Vyleesi) 8 Max doses per month (labeled use) 45 Minutes before activity to inject 24 Hours effect is expected to last Source: PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials, Obstetrics and Gynecology, 2019; PubMed, Bremelanotide: First Approval, Drugs, 2019

What does PT-141 not do

PT-141 doesn't create arousal or lubrication directly, and it doesn't work on erectile tissue or vaginal blood flow the way PDE5 inhibitors do [2] [8]. It's not a fast-acting stimulant that guarantees a physical response; some women report increased desire without a corresponding increase in physical arousal, which can be confusing if you expect a Viagra-like local effect. It's also not approved for men, despite off-label and gray-market interest in bremelanotide for male sexual dysfunction going back to early development work in the 2000s [18] [19]. The approved indication is narrow, specifically premenopausal women with acquired, generalized HSDD [1]. It doesn't fix low desire caused by relationship conflict, another medical condition, or a medication side effect (SSRIs are a common culprit). A 2022 review in Current Psychiatry Reports on pharmacotherapy for female sexual dysfunction stresses that ruling out these other causes is a prerequisite for the HSDD diagnosis PT-141 targets [20]. And it's not a cure. Trial data doesn't show desire staying elevated once someone stops using it; it's used as-needed, before anticipated activity, not as a background treatment that permanently resets baseline desire [5] [11].

What are the most common side effects of PT-141

Nausea and flushing are the two side effects you'll see most consistently across the bremelanotide safety literature, and they're common enough that anyone considering the drug should expect them, not be surprised by them [4] [21]. A 2022 safety profile analysis across the full clinical development program, published in the Journal of Women's Health, pooled data across trials specifically to characterize how often these and other side effects occurred [21]. Nausea tends to be worse with the first couple of doses and often lessens with repeated use, according to trial reporting, though it doesn't disappear for everyone [4] [11]. Headache and injection site reactions (redness, swelling, itching where the shot goes in) also show up. Less common but clinically watched: transient increases in blood pressure after dosing, which is why bremelanotide carries specific guidance around cardiovascular risk factors [22]. A 2022 paper in Medicina (Kaunas) specifically looked at managing hypertension in the context of female sexual dysfunction treatment, underscoring that blood pressure needs consideration before starting a melanocortin agonist, particularly for women with existing cardiovascular risk [22]. This isn't a drug to start without a conversation about your blood pressure history. For the full breakdown of frequency, severity, and how these effects trend over repeated doses, the pt 141 peptide side effects page goes through the safety data in more detail than fits here.

How is PT-141 dosed and administered

Vyleesi comes as a pre-filled autoinjector delivering a subcutaneous dose, self-administered in the abdomen or thigh, at least 45 minutes before anticipated sexual activity [5]. It's used as-needed, not on a daily schedule. Trial dosing in the key phase 3 studies used a fixed dose, and current labeling caps use to no more than one dose within 24 hours and no more than 8 doses per month [5] [11]. That monthly ceiling exists largely because of the blood pressure effect: repeated frequent dosing compounds cardiovascular exposure in a way the trials didn't test extensively beyond that limit. A 2020 review in The Annals of Pharmacotherapy walks through the approval basis and practical dosing considerations for clinicians new to prescribing it [11], and the Medical Letter's 2019 independent drug evaluation covers similar ground with a more skeptical eye toward how much benefit the dosing regimen actually delivers [5]. For a full walkthrough of dose timing, injection technique, and what a typical schedule looks like in practice, see the pt-141 dosage chart and the pt-141 peptide how to use guide. If you're trying to work out where your dose falls relative to trial-tested amounts, the pt-141 dosage calculator is built for that comparison, not for improvising a dose outside labeled use.

Does PT-141 affect the body beyond sexual desire

Because bremelanotide acts on melanocortin receptors that also sit in metabolic and appetite pathways, researchers have looked at whether it does anything measurable to body weight or appetite as a side effect, not a benefit [9] [6]. Two phase 1 randomized controlled trials in obese women specifically tracked body weight as an outcome measure, since MC4R activation is separately being studied for metabolic disease treatment [6]. A 2023 review in Nature Reviews Endocrinology looks at the central melanocortin system broadly as a target for metabolic disorders, which is useful context: bremelanotide isn't unique in touching this receptor family, and MC4R agonism is an active area of obesity drug research entirely separate from the sexual desire indication [9]. There's also early, preclinical research (not clinical, not something a patient should read as a treatment claim) looking at melanocortin receptor agonists including bremelanotide in glioblastoma cell models, where one 2024 study in Anticancer Research found the compound suppressed a protein called survivin and induced cell death in cultured cancer cells [23]. That's laboratory research on cells, years away if ever from any human application, and it says nothing about using PT-141 as approved for HSDD. It's mentioned here only because it shows the melanocortin receptor system has research interest well outside sexual medicine, which helps explain why so much of the mechanistic literature on bremelanotide cites broader melanocortin biology [6] [24].

Who should not take PT-141

Women with uncontrolled high blood pressure or known cardiovascular disease need a real conversation with a prescriber before starting bremelanotide, given the transient blood pressure increases seen after dosing [4] [22]. It's also not approved for use during pregnancy, and it hasn't been studied in postmenopausal women or in men, so prescribing outside that FDA-approved population is off-label territory with a thinner evidence base [1]. A 2022 review in the Urologic Clinics of North America on medical treatment of female sexual dysfunction places bremelanotide within a broader toolkit (alongside flibanserin and other options) and stresses that patient selection, meaning correctly diagnosing HSDD and screening out other causes of low desire, matters as much as the drug choice itself [25]. Anyone with a history of fainting or low blood pressure episodes should also flag that history, since bremelanotide's blood pressure effects go in the other direction from expected but any cardiovascular variability is worth discussing openly with whoever is prescribing [21] [22].

How should someone actually get PT-141 if they want to try it

The only version of bremelanotide with FDA approval, meaning it went through the full clinical trial and safety review process for a specific indication, is Vyleesi, prescribed for diagnosed HSDD in premenopausal women [1]. That's the version with the RECONNECT trial data behind it, the labeled dosing, and the monitored safety profile discussed above [4] [21]. Bremelanotide as a raw peptide also circulates outside that regulated pathway, sold online as "research chemical" PT-141 without a prescription, without dosing guidance, and without any quality assurance. Nothing about that supply chain has been reviewed by the FDA for human use, and it's worth being very clear-eyed about the fact that unregulated PT-141 has no safety data attached to whatever product you'd actually receive. If you're weighing sourcing options, the pt-141 peptide for sale amazon piece walks through why that specific route is a legal and safety dead end. The sensible path is a prescriber conversation: get evaluated for HSDD specifically (ruling out relationship, psychiatric, and medication causes first, as the diagnostic literature recommends [13] [20]), and if bremelanotide is a fit, get it through a provider-reviewed pathway with a legitimate fulfilling pharmacy behind it, rather than an unregulated peptide vendor. Bremelanotide Rx exists to walk through exactly that kind of provider-reviewed route, connecting the clinical picture above to a legitimate path to the medication rather than a gray-market one.

Frequently asked questions

What does PT-141 actually do to the body?

PT-141 (bremelanotide) activates melanocortin receptors, mainly MC4R, in the brain's hypothalamus and related regions, which shifts neural circuits involved in sexual motivation toward increased desire [3][8]. It doesn't act on genital blood vessels. Its FDA-approved use is for acquired, generalized hypoactive sexual desire disorder in premenopausal women, based on phase 3 trial data showing modest but statistically significant improvement in desire scores [1][4].

Is PT-141 the same thing as Vyleesi?

Yes. Vyleesi is the FDA-approved brand name for bremelanotide, also known by the research code PT-141. They're the identical molecule; Vyleesi is simply the regulated, prescription version with labeled dosing, trial data, and FDA oversight behind it, approved in 2019 for premenopausal women with hypoactive sexual desire disorder [1].

How is PT-141's mechanism different from Viagra?

Viagra (sildenafil) is a PDE5 inhibitor that boosts blood flow in genital tissue to support physical arousal once someone is already mentally interested. PT-141 works entirely differently, acting on melanocortin receptors in the brain to affect desire itself, upstream of any vascular response [2][8]. They target different organs and different sexual complaints (arousal versus desire).

How long does it take for PT-141 to work?

In labeled use, Vyleesi is injected at least 45 minutes before anticipated sexual activity, and its effects are understood to taper off within about 24 hours [5]. Trial data doesn't support instant onset; it's not designed as an immediate-acting stimulant, and individual response timing varied across the RECONNECT phase 3 studies [4].

Does PT-141 work for everyone who tries it?

No. Phase 3 trial data showed a statistically significant but modest average improvement in desire scores over placebo, and a 2024 Journal of Sex Research analysis specifically flagged the effect size as small, questioning how meaningful it feels for a typical patient [4][15]. Responder analyses suggest a meaningful subset benefits clearly, but it's not universal.

What are the side effects of PT-141?

Nausea and flushing are the most common side effects, reported consistently across bremelanotide's clinical trials, along with headache and injection site reactions [4][22]. Transient blood pressure increases after dosing are also documented, which is why cardiovascular history matters before starting treatment [23]. Nausea tends to be strongest with early doses and often eases with continued use [12].

Can men use PT-141?

Vyleesi is FDA-approved only for premenopausal women with hypoactive sexual desire disorder; there's no approved indication for men [1]. Bremelanotide research in male sexual dysfunction goes back to early 2000s development work, but that use remains off-label and outside the regulated pathway this article focuses on [19][20].

Is PT-141 safe for someone with high blood pressure?

It needs real caution. Bremelanotide causes transient blood pressure increases after dosing, and a 2022 Medicina (Kaunas) review specifically addresses managing hypertension alongside female sexual dysfunction treatment [23]. Anyone with uncontrolled high blood pressure or cardiovascular disease should discuss this directly with a prescriber before starting, rather than assume it's automatically fine.

How often can you use PT-141?

Labeled use limits Vyleesi to no more than one dose in 24 hours and no more than 8 doses per month [5][12]. That monthly cap exists largely because of the drug's transient blood pressure effect; repeated frequent dosing wasn't extensively tested beyond that limit in the approval trials [4][23].

Does PT-141 cause weight loss?

Bremelanotide acts on MC4R, a receptor also involved in appetite and metabolic regulation, so researchers have studied weight effects specifically. Two phase 1 randomized trials in obese women tracked body weight as an outcome, since melanocortin receptor agonism is separately researched for metabolic disease [9][10]. This isn't an approved or intended use of Vyleesi for sexual desire treatment.

What is hypoactive sexual desire disorder (HSDD)?

HSDD is a diagnosis for persistently low sexual desire that developed after a period of normal desire (acquired), isn't limited to one partner or situation (generalized), and causes personal distress, after other causes like relationship conflict, mental health conditions, or medication side effects have been ruled out [1][14]. It's the specific condition Vyleesi is FDA-approved to treat.

Can you buy PT-141 legally without a prescription?

Vyleesi requires a prescription in the United States, as an FDA-approved drug for a specific diagnosis. Bremelanotide sold online as an unregulated "research chemical" exists outside that framework, without FDA review of manufacturing quality or purity, and using it that way carries risks with no safety data attached to the actual product received.

Sources

  1. PubMed, Bremelanotide: First Approval (Drugs, 2019): Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, approved in 2019.
  2. PubMed, An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder (Expert Opinion on Pharmacotherapy, 2023): Bremelanotide's mechanism works centrally on melanocortin pathways, distinct from vascular mechanisms used by PDE5 inhibitors like sildenafil.
  3. PubMed, Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin (Biomolecules, 2022): Bremelanotide acts as a melanocortin receptor agonist, primarily engaging MC4R.
  4. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019): The RECONNECT phase 3 trials showed statistically significant improvement in FSFI desire scores and reduced FSDS-DAO distress versus placebo, with nausea and flushing as common side effects.
  5. PubMed, Bremelanotide (Vyleesi) for hypoactive sexual desire disorder (The Medical Letter, 2019): Vyleesi is administered by subcutaneous autoinjector at least 45 minutes before anticipated sexual activity, with effects understood to fade within about 24 hours.
  6. PubMed, Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023): Melanocortin receptors, including MC4R, are concentrated in hypothalamic regions tied to appetite and broader central regulatory pathways.
  7. PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology International, 2022): Bremelanotide's action on melanocortin receptors is thought to shift neural signals that promote versus inhibit sexual desire.
  8. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022): Bremelanotide acts on central melanocortin pathways in the brain, a mechanism distinct from peripheral vascular drugs used for sexual dysfunction.
  9. PubMed, Effect of bremelanotide on body weight of obese women (Diabetes, Obesity & Metabolism, 2022): Two phase 1 randomized controlled trials tracked body weight as an outcome in obese women given bremelanotide, given MC4R's role in metabolic regulation.
  10. PubMed, Bremelanotide: the female Viagra? (Expert Review of Endocrinology & Metabolism, 2006): Early literature on bremelanotide used the 'female Viagra' framing despite the drug having a different mechanism than sildenafil.
  11. PubMed, Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (The Annals of Pharmacotherapy, 2020): Dosing guidance limits bremelanotide to specific frequency, and nausea tends to lessen with repeated dosing according to clinical review.
  12. PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021): A critical review argues comparing bremelanotide and flibanserin to erectile dysfunction drug precedent is a regulatory fallacy given different effect sizes and disease framing.
  13. PubMed, Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment (Journal of Midwifery & Women's Health, 2021): Diagnosing HSDD requires ruling out other causes of low desire such as relationship issues, mental health conditions, and medication side effects.
  14. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024): A re-examination of bremelanotide trial data found the clinical effect size was modest, raising questions about meaningfulness for typical patients.
  15. PubMed, Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder' in Women (Journal of Sex Research, 2021): A separate re-analysis of the phase 3 bremelanotide data raised questions about how trial results were originally framed.
  16. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (The Journal of Sexual Medicine, 2019): A responder analysis examined the proportion of women achieving a clinically meaningful improvement threshold in a phase 2b dose-ranging study.
  17. PubMed, Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (Journal of Women's Health, 2022): Subgroup analyses of RECONNECT trial data examined whether patient characteristics affected treatment response.
  18. PubMed, Bremelanotide (2006): Early bremelanotide development work in the mid-2000s explored its effects in both male and female sexual dysfunction.
  19. PubMed, Melanocortins in the treatment of male and female sexual dysfunction (Current Topics in Medicinal Chemistry, 2007): Melanocortin receptor agonists including bremelanotide were studied for both male and female sexual dysfunction in early research.
  20. PubMed, Pharmacotherapy for Sexual Dysfunction in Women (Current Psychiatry Reports, 2022): Ruling out other causes of low desire is a prerequisite for the HSDD diagnosis that bremelanotide pharmacotherapy targets.
  21. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022): Pooled safety data across the clinical development program characterized frequency of nausea, flushing, headache, and injection site reactions.
  22. PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): Bremelanotide causes transient blood pressure increases after dosing, requiring consideration of cardiovascular risk before treatment.
  23. PubMed, Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression (Anticancer Research, 2024): A preclinical cell-culture study found bremelanotide suppressed survivin expression and induced cell death in glioblastoma cells.
  24. PubMed, Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases (Diseases, 2025): Melanocortin receptor genes are studied broadly for roles in inflammatory traits and disease beyond sexual medicine.
  25. PubMed, Medical Treatment of Female Sexual Dysfunction (The Urologic Clinics of North America, 2022): Correct patient selection and diagnosis of HSDD matters as much as drug choice when considering bremelanotide within the broader treatment toolkit.